Results 161 to 170 of about 81,723 (303)

Janus Kinase Inhibitor Upadacitinib in Elderly-Onset Rheumatoid Arthritis With Hip Osteoarthritis: A Case Report. [PDF]

Am J Case Rep
Sanji Y, Matsushita I, Takahashi E, Fukui M, Kitajima H, Kaneuji A.   +5 more
europepmc   +1 more source

Exploring market dynamics of biological including biosimilar treatments for retinal diseases in Europe: An interrupted time‐series analysis

Acta Ophthalmologica, EarlyView.
Abstract Purpose To assess the impact of biosimilar ranibizumab and on‐patent faricimab market entry on pricing and utilization trends and describe national variation in off‐label bevacizumab use in Europe. Methods Interrupted time series analysis of quarterly sales data (Q1 2018–Q2 2024) in 11 European countries evaluated ranibizumab utilization and ...
Elif Car, Isabelle Huys, Steven Simoens, Arnold G. Vulto   +3 more
wiley   +1 more source

Janus Kinase Inhibitor Discontinuation at a UK Tertiary Centre: A Retrospective Study. [PDF]

Cureus
Bland K, Jubber A, Ganguly S, Moorthy A.
europepmc   +1 more source

One‐Year Effectiveness of Upadacitinib in Perianal Crohn's Disease: A Real‐World GETAID Study

Alimentary Pharmacology &Therapeutics, EarlyView.
In a real‐world cohort of patients with highly refractory perianal Crohn's disease, upadacitinib induced clinical remission at 12 months in 26% of patients with fistulizing disease and 25% of those with isolated anal ulcerations. ABSTRACT Introduction Upadacitinib (UPA) is effective for treating luminal Crohn's disease (CD), but data on perianal CD ...
Nicolas Richard, Philippe Seksik, Romain Altwegg, Maria Nachury, David Laharie, Stéphane Nancey, Benoît Coffin, Anne‐Laure Pelletier, Mathieu Uzzan, Aurélien Amiot, Morgane Amil, Lucine Vuitton, Mathurin Fumery, Anne Bozon   +13 more
wiley   +1 more source

A multicentre analysis of efficacy, safety and molecular response correlates of fostamatinib in warm autoimmune haemolytic anaemia and Evans syndrome

British Journal of Haematology, EarlyView.
Fostamatinib had 46% durable response, with 73% steroid reduction, in this multicentre retrospective study of refractory wAIHA/ES. Hypertension, gastrointestinal (GI) distress and neutropenia occurred in 23%. Only one patient required drug discontinuation and one patient dose reduction.
Jorge N. Ruiz Lopez, Lipei Shao, Debbie Jiang, Lawrence S. Bailey, Thejaswi Bikkani, Aaron Boothby, Donald C. Moore, Irina Murakhovskaya, Caroline I. Piatek, Mauricio Pineda‐Roman, Ping Jin, Jacqueline N. Poston, Moritz Stolla, David F. Stroncek, Krystalyn E. Hudson, James B. Bussel, Sandhya R. Panch   +16 more
wiley   +1 more source

Pharmacokinetics of Ilunocitinib, a New Janus Kinase Inhibitor, in Dogs. [PDF]

J Vet Pharmacol Ther
Boerngen K, Patel Y, Pittorino M, Toutain CE.   +3 more
europepmc   +1 more source

Janus kinase inhibitor therapy for the treatment of spondyloenchondrodysplasia with immune dysregulation due to novel <i>ACP5</i> variants: a multicenter study. [PDF]

Front Immunol
Mu H, Liu L, Chen Z, Chen R, Liu X, Wu J, Yang X, Tang X, Zhou L, Jia Y, Patra PK, Wani NA, Gupta S, Zhao X, Banday AZ, An Y.   +15 more
europepmc   +1 more source

Integrated proteomic and metabolomic profiling reveals sex‐stratified biomarkers predicting chronicity in paediatric primary immune thrombocytopenia

British Journal of Haematology, EarlyView.
Construction of the immune thrombocytopenia (ITP) chronicity prediction model was based on sex‐stratified multi‐omics analysis, identifying key sex‐specific predictors (intercellular adhesion molecule‐1 [ICAM‐1] and biopterin in males; actin, alpha 2, smooth muscle, aorta [ACTA‐2] and N6‐acetyl‐L‐lysine in females).
Yuanyuan Xue, Rongrong Zhang, Dongmei Liang, Yupeng Xu, Zhaofang Tian, Xiaohong Dai, Wei Xu, Qingqing Cao, Haiyan Zhu, Yun Wang, Yufang Yuan   +10 more
wiley   +1 more source

Progression of mycosis fungoides in a patient receiving a Janus kinase inhibitor. [PDF]

JAAD Case Rep
Stankiewicz JM, Kersten JM, Merkus VA, de Haan S, Jansen PM, Vermeer MH, Ottevanger R.   +6 more
europepmc   +1 more source

Effect of JAK inhibitors on release of CXCL9, CXCL10 and CXCL11 from human airway epithelial cells [PDF]

, 2015
Barnes, PJ, Donnelly, LE, Fenwick, PS, Macedo, P   +3 more
core   +1 more source